Literature DB >> 31789046

Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma.

Minkyo Song1, Bryan A Bassig1, Noemi Bender2, James J Goedert1, Cheryl A Winkler3,4, Nicole Brenner2,5, Tim Waterboer2, Charles S Rabkin1.   

Abstract

Infection with human immunodeficiency virus (HIV) is associated with substantially increased incidence of non-Hodgkin lymphoma (NHL). This risk may be driven, in part, by reduced immune control over viral infections in the setting of acquired immunodeficiency syndrome (AIDS), although the lymphomagenic mechanisms are not yet established. We used bead-based multiplex assays to measure antibody seroreactivity to 32 viral antigens representing 22 different viral infections (human herpesviruses 1-8, hepatitis B and C virus, human T-lymphotropic virus type-1, and human polyomaviruses) in two prospective HIV cohorts. Incident (n = 28) and prevalent (n = 38) AIDS-related NHL cases were matched by age, sex, race, and CD4 count to 67 HIV-positive control individuals without AIDS-NHL. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations of AIDS-NHL with the number of different viruses to which an individual was seropositive and seroreactivity to individual antigens. Seropositivity to an increasing number of viruses was inversely associated with AIDS-NHL (OR per virus = 0.84, 95% CI = 0.72-0.98). Seroreactivity to herpes simplex virus 2 2mgG unique antigen (OR = 0.47; 95% CI = 0.23-0.97) and to WU polyomavirus viral capsid protein (OR = 0.26, 95% CI = 0.10-0.65) was significantly lower in AIDS-NHL cases compared to controls. In this evaluation of antibodies to multiple viruses, we observed an inverse association between seropositivity to a larger number of viruses and AIDS-NHL. While in need of further evaluation, our data raise the novel hypothesis that insufficient exposures or impaired humoral immune responses to viral infections may be associated with AIDS-related lymphomagenesis.

Entities:  

Keywords:  AIDS-related non-Hodgkin lymphoma; antiviral antibodies; multiplex serology

Mesh:

Substances:

Year:  2020        PMID: 31789046      PMCID: PMC7232664          DOI: 10.1089/AID.2019.0208

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  41 in total

1.  Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Authors:  Caroline Besson; Remi Lancar; Sophie Prevot; Michele Algarte-Genin; Pierre Delobel; Fabrice Bonnet; Marie-Caroline Meyohas; Marialuisa Partisani; Lucie Oberic; Jean Gabarre; Cécile Goujard; François Boue; Paul Coppo; Regis Costello; Houria Hendel-Chavez; Nawel Mekerri; Gabriella Dos Santos; Christian Recher; Richard Delarue; Rene-Olivier Casasnovas; Yassine Taoufik; Nicolas Mounier; Dominique Costagliola
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

2.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.

Authors:  Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

3.  Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study.

Authors:  Todd M Gibson; Lindsay M Morton; Meredith S Shiels; Christina A Clarke; Eric A Engels
Journal:  AIDS       Date:  2014-09-24       Impact factor: 4.177

4.  Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma.

Authors:  Eric A Engels; Dana E Rollison; Patricia Hartge; Dalsu Baris; James R Cerhan; Richard K Severson; Wendy Cozen; Scott Davis; Robert J Biggar; James J Goedert; Raphael P Viscidi
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

5.  Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions.

Authors:  Therese Högfeldt; Crystal Jaing; Kevin Mc Loughlin; James Thissen; Shea Gardner; Abeer A Bahnassy; Baback Gharizadeh; Joachim Lundahl; Anders Österborg; Anna Porwit; Abdel-Rahman N Zekri; Hussein M Khaled; Håkan Mellstedt; Ali Moshfegh
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

6.  Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study.

Authors:  Laura Waters; Justin Stebbing; Sundhiya Mandalia; Anne Marie Young; Mark Nelson; Brian Gazzard; Mark Bower
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

7.  Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus.

Authors:  J J Goedert; R J Biggar; M Melbye; D L Mann; S Wilson; M H Gail; R J Grossman; R A DiGioia; W C Sanchez; S H Weiss
Journal:  JAMA       Date:  1987-01-16       Impact factor: 56.272

Review 8.  Pathology of lymphoma in HIV.

Authors:  Ethel Cesarman
Journal:  Curr Opin Oncol       Date:  2013-09       Impact factor: 3.645

9.  WU Polyomavirus (WUPyV): A Recently Detected Virus Causing Respiratory Disease?

Authors:  Michael Kleines; Martin Häusler; Alexander Krüttgen; Simone Scheithauer
Journal:  Viruses       Date:  2009-11-04       Impact factor: 5.048

10.  Hepatitis C virus and non-Hodgkin's lymphoma: Findings from the Swiss HIV Cohort Study.

Authors:  S Franceschi; J Polesel; M Rickenbach; L Dal Maso; N M Probst-Hensch; C Fux; M Cavassini; B Hasse; A Kofler; B Ledergerber; P Erb; G M Clifford
Journal:  Br J Cancer       Date:  2006-11-14       Impact factor: 7.640

View more
  2 in total

Review 1.  Functional Domains of the Early Proteins and Experimental and Epidemiological Studies Suggest a Role for the Novel Human Polyomaviruses in Cancer.

Authors:  Ugo Moens; Carla Prezioso; Valeria Pietropaolo
Journal:  Front Microbiol       Date:  2022-02-18       Impact factor: 5.640

2.  Global, regional and national burden of non-Hodgkin lymphoma from 1990 to 2017: estimates from global burden of disease study in 2017.

Authors:  Haifeng Sun; Li Xue; Yahuan Guo; Jianqiang Du; Kejun Nan; Ming Li
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.